Daytrana and Remicade drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Daytrana (methylphenidate) and Remicade (infliximab). Common drug interactions include hypersensitivity among females and irritability among males.

The phase IV clinical study analyzes what interactions people have when they take Daytrana and Remicade. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Daytrana?

Daytrana has active ingredients of methylphenidate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 16,561 Daytrana users. Check the latest studies of Daytrana.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 224,011 Remicade users. Check the latest studies of Remicade.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

18 people who take Daytrana and Remicade together, and have interactions are studied.

Daytrana and Remicade drug interactions.

What are the common drug interactions of Daytrana and Remicade, by gender? *:

female:

Hypersensitivity
Infusion related reaction
Loss of consciousness
Malaise (a feeling of general discomfort or uneasiness)
Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas)
Small intestinal stenosis (abnormal narrowing of small intestine)
Therapeutic response unexpected

male:

Irritability
Pruritus (severe itching of the skin)
Drug ineffective
Fall
Gait disturbance
Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
Muscle spasms (muscle contraction)
Muscular weakness (muscle weakness)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Rash

What are the common drug interactions of Daytrana and Remicade, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
Muscle spasms (muscle contraction)
Muscular weakness (muscle weakness)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Rash
Stiff person syndrome
Upper respiratory tract infection
Anaemia (lack of blood)
Anti-gad antibody positive
Back pain

10-19:

Irritability
Pruritus (severe itching of the skin)
Hypersensitivity
Infusion related reaction
Loss of consciousness
Malaise (a feeling of general discomfort or uneasiness)
Small intestinal stenosis (abnormal narrowing of small intestine)

20-29:

n/a

30-39:

Drug effect decreased
Overdose

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Migraine (headache): 4 people, 22.22%
Hypersensitivity: 4 people, 22.22%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 22.22%
Depression: 4 people, 22.22%
Mental Disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability): 3 people, 16.67%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 2 people, 11.11%
Inflammatory Bowel Disease: 2 people, 11.11%
Disturbance In Attention: 2 people, 11.11%
Thyroid Diseases: 1 person, 5.56%
Therapeutic Response Decreased (less preventive response): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Daytrana and Remicade?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously